ZBTB34

Summary

ZBTB34 (zinc finger and BTB domain containing 34, HGNC:31446) is a protein-coding gene on chromosome 9q33.3, encoding Zinc finger and BTB domain-containing protein 34 (Q8NCN2). May be a transcriptional repressor.

Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II; regulation of cytokine production; and regulation of immune system process. Located in nucleoplasm.

Source: NCBI Gene 403341 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 66 total
• MANE Select transcript: NM_001099270

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31446
Approved symbol	ZBTB34
Name	zinc finger and BTB domain containing 34
Location	9q33.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1993, MGC24652, ZNF918
Ensembl gene	ENSG00000177125
Ensembl biotype	protein_coding
OMIM	611692
Entrez	403341

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000319119, ENST00000695642, ENST00000921402, ENST00000921403

RefSeq mRNA: 2 — MANE Select: NM_001099270 NM_001099270, NM_001395198

CCDS: CCDS48023, CCDS94483

Canonical transcript exons

ENST00000319119 — 2 exons

Exon	Start	End
ENSE00001259345	126879390	126885878
ENSE00001423590	126860639	126860739

Expression profiles

Bgee: expression breadth ubiquitous, 246 present calls, max score 88.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.1666 / max 48.4883, expressed in 1429 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
98579	3.1666	1429

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amniotic fluid	UBERON:0000173	88.26	gold quality
cortical plate	UBERON:0005343	87.93	gold quality
upper arm skin	UBERON:0004263	85.73	gold quality
monocyte	CL:0000576	85.57	gold quality
leukocyte	CL:0000738	85.21	gold quality
tibia	UBERON:0000979	84.70	gold quality
blood	UBERON:0000178	84.36	gold quality
upper leg skin	UBERON:0004262	83.57	gold quality
ileal mucosa	UBERON:0000331	83.35	gold quality
adrenal tissue	UBERON:0018303	82.81	gold quality
germinal epithelium of ovary	UBERON:0001304	81.95	gold quality
bone marrow	UBERON:0002371	81.95	gold quality
visceral pleura	UBERON:0002401	81.83	gold quality
parietal pleura	UBERON:0002400	81.39	gold quality
palpebral conjunctiva	UBERON:0001812	81.23	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.12	gold quality
tibialis anterior	UBERON:0001385	80.05	gold quality
placenta	UBERON:0001987	79.79	gold quality
deltoid	UBERON:0001476	79.05	silver quality
esophagus squamous epithelium	UBERON:0006920	79.03	gold quality
pancreatic ductal cell	CL:0002079	78.92	gold quality
skin of hip	UBERON:0001554	78.83	gold quality
epithelial cell of pancreas	CL:0000083	78.72	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.71	gold quality
primary visual cortex	UBERON:0002436	78.67	gold quality
pigmented layer of retina	UBERON:0001782	78.58	gold quality
epithelium of nasopharynx	UBERON:0001951	78.51	gold quality
bone marrow cell	CL:0002092	78.26	gold quality
Brodmann (1909) area 23	UBERON:0013554	77.18	gold quality
granulocyte	CL:0000094	76.99	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.85

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

361 targeting ZBTB34, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996

Literature-anchored findings (GeneRIF, showing 1)

• This present work as the first report about the functional exploration of the novel ZBTB34 gene would be contributed to profound understanding of the transcriptional regulation via BTB/POZ protein family. (PMID:16718364)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zbtb34	ENSDARG00000013492
mus_musculus	Zbtb34	ENSMUSG00000068966
rattus_norvegicus	Zbtb34	ENSRNOG00000032700

Paralogs (36): ZNF302 (ENSG00000089335), ZNF184 (ENSG00000096654), CTCF (ENSG00000102974), ZNF574 (ENSG00000105732), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF473 (ENSG00000142528), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF91 (ENSG00000167232), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZNF771 (ENSG00000179965), ZNF48 (ENSG00000180035), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZBTB48 (ENSG00000204859), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)

Protein

Protein identifiers

Zinc finger and BTB domain-containing protein 34 — Q8NCN2 (reviewed: Q8NCN2)

All UniProt accessions (2): A0A0C4DFQ2, A0A8Q3WKM1

UniProt curated annotations — full annotation on UniProt →

Function. May be a transcriptional repressor.

Subcellular location. Nucleus.

Tissue specificity. Expressed in several tissues, including heart, brain, thymus, skeletal muscle, small intestine, testis, kidney, placenta, peripheral blood cells and adult and fetal liver.

RefSeq proteins (2): NP_001092740, NP_001382127 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050457	ZnFinger_BTB_dom_contain	Family

Pfam: PF00096, PF00651, PF13894

UniProt features (17 total): cross-link 4, region of interest 4, zinc finger region 3, compositionally biased region 2, modified residue 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NCN2-F1	55.17	0.11

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 164, 463, 235, 237, 426, 474

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 177 (showing top): GOBP_CYTOKINE_PRODUCTION, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GEORGES_TARGETS_OF_MIR192_AND_MIR215, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, LU_EZH2_TARGETS_DN, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOMF_DNA_BINDING_TRANSCRIPTION_REPRESSOR_ACTIVITY, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, GSE14415_NATURAL_TREG_VS_TCONV_UP, HAND1_TARGET_GENES, HMG20B_TARGET_GENES, RLF_TARGET_GENES, TAFAZZIN_TARGET_GENES

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of cytokine production (GO:0001817), regulation of immune system process (GO:0002682)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): chromatin (GO:0000785), nucleoplasm (GO:0005654), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of transcription by RNA polymerase II	2
cellular anatomical structure	2
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cytokine production	1
regulation of gene expression	1
regulation of multicellular organismal process	1
immune system process	1
regulation of biological process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
chromosome	1
nuclear lumen	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

550 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZBTB34	LGALS4	P56470	648
ZBTB34	RPP14	O95059	480
ZBTB34	RHBDD2	Q6NTF9	424
ZBTB34	TASP1	Q9H6P5	388
ZBTB34	GABRR3	A8MPY1	386
ZBTB34	NDFIP2	Q9NV92	381
ZBTB34	JMJD4	Q9H9V9	360
ZBTB34	IMPG1	Q17R60	354
ZBTB34	DARS2	Q6PI48	349
ZBTB34	DRC3	Q9H069	339
ZBTB34	CAMSAP1	Q5T5Y3	333
ZBTB34	WBP2	Q969T9	331
ZBTB34	MANBAL	Q9NQG1	326
ZBTB34	RAB11FIP2	Q7L804	325
ZBTB34	GAPVD1	Q14C86	324

IntAct

36 interactions, top by confidence:

A	B	Type	Score
ZBTB34	TDRKH	psi-mi:“MI:0915”(physical association)	0.670
ZBTB34	BACH2	psi-mi:“MI:0915”(physical association)	0.670
KLHL22	TMEM223	psi-mi:“MI:0914”(association)	0.640
ZBTB34	PIAS4	psi-mi:“MI:0915”(physical association)	0.560
ZBTB34	RNF4	psi-mi:“MI:0915”(physical association)	0.560
ZBTB34	ZBTB26	psi-mi:“MI:0915”(physical association)	0.560
PIAS4	ZBTB34	psi-mi:“MI:0915”(physical association)	0.560
RNF4	ZBTB34	psi-mi:“MI:0915”(physical association)	0.560
FOXP3	FOXP2	psi-mi:“MI:0914”(association)	0.530
FOXN3	RFX1	psi-mi:“MI:0914”(association)	0.530
FOXC2	ZNF536	psi-mi:“MI:0914”(association)	0.350
FOXE1	DDX39A	psi-mi:“MI:0914”(association)	0.350
FOXJ2	TCERG1	psi-mi:“MI:0914”(association)	0.350
PB2	ESYT2	psi-mi:“MI:0914”(association)	0.350
L3MBTL1	ZNF195	psi-mi:“MI:0914”(association)	0.350
TH	MAP3K7	psi-mi:“MI:0914”(association)	0.350
FOXN3	RFX1	psi-mi:“MI:0914”(association)	0.350
ZBTB34	KPNA3	psi-mi:“MI:0914”(association)	0.350
ABTB2	IFT56	psi-mi:“MI:0914”(association)	0.350
FBLN5	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZBTB34	CHEK1	psi-mi:“MI:0914”(association)	0.350
ZBTB24	BACH1	psi-mi:“MI:0914”(association)	0.350
TDRKH	ESPL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (37): ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Affinity Capture-MS), ZBTB34 (Two-hybrid), ZBTB34 (Two-hybrid), ZBTB34 (Two-hybrid), ZBTB34 (Two-hybrid), TDRKH (Two-hybrid), ZBTB34 (Affinity Capture-MS), BACH2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5NS60, A0JN76, A1L2U9, B1WAZ8, E9Q3T6, O15060, O15062, O35260, O93567, P41182, P41183, Q05516, Q0IH98, Q0IJ29, Q0P4X6, Q0V8G8, Q1L8W0, Q3B725, Q3B7N9, Q3SWU4, Q5EAC5, Q5EXX3, Q5R5N5, Q5SW75, Q5ZM39, Q6DDV0, Q6NRK3, Q6NRM8, Q6ZSB9, Q7TQG0, Q7TS63, Q7TSZ8, Q7ZWZ4, Q801P1, Q80X44, Q86VK4, Q8BKX7, Q8BXX2, Q8CII0, Q8NAP3

Diamond homologs: A0A1B8YAB1, A1YPR0, B0WWP2, B1H285, B3M9V8, B3NDN0, B4GRJ2, B4HIK1, B4J045, B4L0G9, B4LIG6, B4MXW3, B4PD06, B4QLQ2, C9JR72, D3Z8N4, E0CZ16, G3X9X1, O15062, O88939, O93567, O95365, P28575, P41182, P41183, Q08CL3, Q08DK3, Q13105, Q16RL8, Q2M0J9, Q3UQV5, Q52KB5, Q5EXX3, Q5R7B8, Q5RDY3, Q5TC79, Q5ZI33, Q5ZKD9, Q5ZM39, Q60821

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

254 predictions. Top by Δscore:

Variant	Effect	Δscore
9:126880915:GATG:G	donor_gain	0.9900
9:126880924:G:GT	donor_gain	0.9900
9:126885156:GTAA:G	acceptor_gain	0.9700
9:126885156:G:GA	acceptor_gain	0.9100
9:126879598:T:G	donor_gain	0.8600
9:126880813:GATGT:G	donor_gain	0.8400
9:126885157:T:G	acceptor_gain	0.8000
9:126882811:G:GC	acceptor_gain	0.7900
9:126880713:G:GT	donor_gain	0.7500
9:126880914:AGATG:A	donor_loss	0.7300
9:126880916:ATG:A	donor_loss	0.7300
9:126880917:TGGT:T	donor_loss	0.7300
9:126880918:GGTAA:G	donor_loss	0.7300
9:126880919:GTAAA:G	donor_loss	0.7300
9:126880920:T:A	donor_loss	0.7300
9:126880921:A:T	donor_loss	0.7300
9:126880713:G:T	donor_gain	0.7200
9:126880967:A:AG	donor_gain	0.7200
9:126880878:G:GT	donor_gain	0.7000
9:126880922:A:G	donor_loss	0.6900
9:126880968:T:G	donor_gain	0.6800
9:126885572:A:AG	acceptor_gain	0.6800
9:126885155:A:AG	acceptor_gain	0.6700
9:126879597:GT:G	donor_gain	0.6600
9:126879598:TT:T	donor_gain	0.6600
9:126880814:A:G	donor_gain	0.6600
9:126885156:GTA:G	acceptor_gain	0.6600
9:126880894:GT:G	donor_gain	0.6500
9:126880911:T:TG	donor_gain	0.6400
9:126879598:T:TG	donor_gain	0.6300

AlphaMissense

3359 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:126880531:T:C	C374R	1.000
9:126880532:G:A	C374Y	1.000
9:126880533:T:G	C374W	1.000
9:126880540:T:C	C377R	1.000
9:126880541:G:A	C377Y	1.000
9:126880542:T:G	C377W	1.000
9:126880552:T:C	F381L	1.000
9:126880553:T:C	F381S	1.000
9:126880554:C:A	F381L	1.000
9:126880554:C:G	F381L	1.000
9:126880571:T:C	L387P	1.000
9:126880615:T:C	C402R	1.000
9:126880617:C:G	C402W	1.000
9:126880636:T:G	Y409D	1.000
9:126880643:G:C	R411P	1.000
9:126880655:T:C	L415P	1.000
9:126880663:C:G	H418D	1.000
9:126880665:C:A	H418Q	1.000
9:126880665:C:G	H418Q	1.000
9:126880699:T:C	C430R	1.000
9:126880701:T:G	C430W	1.000
9:126880708:T:C	C433R	1.000
9:126880720:T:C	F437L	1.000
9:126880721:T:C	F437S	1.000
9:126880722:T:A	F437L	1.000
9:126880722:T:G	F437L	1.000
9:126880739:T:C	L443P	1.000
9:126879476:T:C	L22P	0.999
9:126880531:T:A	C374S	0.999
9:126880532:G:C	C374S	0.999

dbSNP variants (sampled 300 via entrez): RS1000000472 (9:126872590 ACCT>A), RS1000004702 (9:126878222 G>A,C), RS1000096914 (9:126872908 G>A), RS1000149392 (9:126872596 T>G), RS1000354866 (9:126866953 T>A,C), RS1000430756 (9:126860879 C>G,T), RS1000608731 (9:126876914 T>C), RS1000667830 (9:126883345 A>G), RS1000878281 (9:126866009 C>T), RS1000916319 (9:126877194 C>T), RS1000983779 (9:126885256 C>T), RS1000995282 (9:126885009 A>G), RS1001000277 (9:126871483 C>T), RS1001182218 (9:126866320 A>T), RS1001282992 (9:126872092 G>A)

Disease associations

OMIM: gene MIM:611692 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003476_10	Eyebrow thickness	3.000000e-06
GCST010703_39	Brain morphology (MOSTest)	9.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases stability, increases expression	2
Benzo(a)pyrene	increases expression, increases mutagenesis	2
Formaldehyde	decreases expression, increases expression	2
Tobacco Smoke Pollution	increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects expression, increases methylation	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
abrine	decreases expression	1
NSC 689534	affects binding, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Cisplatin	affects expression	1
Copper	affects binding, increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	increases expression, affects cotreatment	1
Testosterone	decreases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice